2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5922 Cartiac: Comparative cardiovascular safety of CAR T products for non-Hodgkin’s lymphoma – a propensity Score–Matched international multicenter study

Mohammad Alhomoud, MD, Ali Abed Al Wahad, MD2, David Nemirovsky, MS3, Samantha Brown4, Uri Greenbaum, MD5, Tobias Tix, MD6, James Di Palma-Grisi, MD7, Elan Baskir8, Parastoo B. Dahi, MD9, Alessandra Holzem, MD10, Linus Kruk, MD11, Marion Subklewe I, MD12, Sandeep Sunder Raj, MD13, Marina Gomez-Llobell, MD14, Sigrun Einarsdottir, MD, PhD15, Sapir Israeli16, Silvia Escribano Serrat, MD17, Roi Westreich18, Noa Golan Accav19, Ori Ben Valid20, Ronit Marcus, MD21, Avichai Shimoni, MD22, Arnon Nagler I, MD23, Manhal Habib24, Jabour Halloun, MD25, Richard J. Lin, MD, PhD26, Michael Scordo, MD27, Gunjan L. Shah, MD, MS28, Craig Sauter, MD29, Ofrat Beyar-Katz, MD, PhD30, Gilles Salles I, MD, PhD31, Sarah Samorodnitsky, PhD32, Jae H Park, MD33, Maria Lia Palomba, MD34, Miguel-Angel Perales, MD35, Roni Shouval Jr, MD, PhD36, Abraham Avigdor, MD37, Andrew Ip, MD, MS38, Kai Rejeski, MD39, Jennifer Liu40
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Rambam Medical Center, Haifa, Israel
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, United States
5 Soroka University Medical center and Faculty of Health and Science, Israel, Israel
6 LMU, Munich, Germany
7 Hackensack Meridien Health, NJ, United States
8 Memorial Sloan Kettering Cancer Center, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, United States
10 LMU, Munich, Germany
11 LMU, Munich, Germany
12 LMU, Munich, Germany
13 Memorial Sloan Kettering Cancer Center, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, United States
18 Soroka University Medical center and Faculty of Health and Science, Israel, Israel
19 Sheba Medical Center, Tel Aviv, Israel
20 Sheba Medical Center, Tel Aviv, Israel
21 Sheba Medical Center, Tel Aviv, Israel
22 Sheba Medical Center, Tel Aviv, Israel
23 Sheba Medical Center, Tel Aviv, Israel
24 Rambam Medical Center, Haifa, Israel
25 Rambam Medical Center, Haifa, Israel
26 Memorial Sloan Kettering Cancer Center, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York, United States
29 Memorial Sloan Kettering Cancer Center, New York, United States
30 Rambam Medical Center, Haifa, Israel
31 Memorial Sloan Kettering Cancer Center, New York, United States
32 Memorial Sloan Kettering Cancer Center, New York, United States
33 Memorial Sloan Kettering Cancer Center, New York, United States
34 Memorial Sloan Kettering Cancer Center, New York, United States
35 Memorial Sloan Kettering Cancer Center, New York, United States
36 Memorial Sloan Kettering Cancer Center, New York, United States
37 Sheba Medical Center, Tel Aviv, Israel
38 Hackensack Meridien Health, NJ, United States
39 LMU, Munich, Germany
40 Memorial Sloan Kettering Cancer Center, New York, United States

Background: Recipients of CD19 chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma are typically older and frequently have baseline cardiovascular (CV) comorbidities, placing them at increased risk for CV complications. Although observational studies suggest an increased risk of CAR T–associated cardiotoxicity, it remains unclear whether CV risk varies among CAR T products and whether these differences inform product selection. To address this gap, we performed a propensity score–adjusted analysis comparing CV safety across FDA-approved CD19 CAR T-cell products.

Methods: CAR T–induced Adverse Cardiotoxicity (CARTiAC) is an international retrospective study spanning six centers across three countries. Patients treated with CD19-CAR-T for large B-cell lymphoma (LBCL) and follicular lymphoma were included. Investigators used a standardized data collection framework to capture CV events occurring from the start of lymphodepletion (LD) through day 30 post-infusion. Propensity score models for CAR T product balanced key characteristics, including age, performance status, tumor burden, bridging therapy, and CV risk factors, between CAR T groups. Inverse probability weighting was subsequently applied to generate balanced groups, and weighted logistic regression models were used to estimate adjusted odds of day 30 CV events. 

Results: A total of 1004 adult patients treated with CAR T were included in this analysis: axi-cel (58%), liso-cel (21%), and tisa-cel (21%). Median age was 65 years (interquartile range [IQR], 56–73), 59% were male, and 67% received bridging therapy. LBCL was the predominant diagnosis (91%). Median follow-up was 27 months. Overall, 67% had ≥1 known CV risk factor, most commonly hypertension (40%), active or prior smoking (32%), diabetes (18%), arrhythmias (14%), coronary artery disease (9%), and heart failure with reduced ejection fraction (8%). Approximately one-fifth of patients (17%) had three or more baseline CV risk factors.

Overall, 8% (n=85) of patients experienced CV events between LD and day 30 following CAR T-cell infusion. The highest incidence was observed with tisa-cel (15%), followed by axi-cel (8%) and liso-cel (4%). The median time to the first CV event was 6 days post infusion for both tisa-cel and axi-cel (tisa-cel IQR, 4-7; axi-cel IQR, 4-9), and 8 days for liso-cel (IQR, 0-14). Overall, the most common events were atrial arrhythmias, including atrial fibrillation and flutter (45%), followed by supraventricular tachycardia (15%) and heart failure (12%). Other CV events, including acute coronary syndrome, ventricular arrhythmias, cerebrovascular events, myocarditis, pericarditis and pericardial effusion, accounted for the remaining 28% of events. CAR T–specific toxicities were more common among patients who developed CV events. Any-grade cytokine release syndrome (CRS) occurred in 91% of patients who experienced CV events compared with 75% of those without CV events. Grade ≥2 CRS was also more frequent in the CV event cohort (62% vs. 32%). Similarly, any-grade immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 53% of patients with CV events compared with 29% of those without CV events, while grade ≥2 ICANS occurred in 32% vs. 19%, respectively.

In propensity score-adjusted analyses accounting for age, performance status, bridging therapy, Pre-LD LDH, and baseline CV risk factors, tisa-cel was associated with a significantly higher risk of CV events by day 30 compared with axi-cel (odds ratio [OR], 1.9, 95% confidence interval [CI] 1.13–3.27; P=0.02). In contrast, liso-cel was associated with a significantly lower CV event rate compared with axi-cel (OR, 0.20, 95% CI 0.07–0.48; P<0.001). Overall, patients who developed a CV event by day 30 had inferior 1-year OS compared with those without a CV events (59%, 95% CI 49–71% vs. 75%, 95% CI 72–78% P<0.001).

Conclusions: In the largest multicenter international cohort to date, comprising patients with baseline CV comorbidities representative of real-world practice, we characterized the landscape of early CAR T-cell–associated CV complications. Propensity score-adjusted analyses demonstrated that liso-cel was associated with a more favorable CV safety profile than axi-cel, whereas tisa-cel was associated with a higher risk of early CV events. These findings may inform individualized CAR T-cell product selection, particularly for patients with preexisting CV disease or those at high CV risk.

Mohammad Alhomoud, MD: No relevant conflicts of interest to declare.